Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma

Key facts

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Principal Investigator

Huaiwu Lu

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Intervention

Treatment(drug)

Enrollment

36 enrolled

Eligibility

18-75 years · FEMALE

Timeline

2026 – 2029

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell adenocarcinoma of the ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06677190
  Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
  Dana-Farber Cancer Institute
• RECRUITINGPHASE1, PHASE2NCT06065462
  Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
  M.D. Anderson Cancer Center
• RECRUITINGNCT06279104
  A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
  Tongji Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT05296512
  Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
  Elizabeth K. Lee MD
• ACTIVE NOT RECRUITINGPHASE2NCT05032040
  A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
  Xencor, Inc.
• ACTIVE NOT RECRUITINGPHASE1NCT05226507
  A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
  Nuvectis Pharma, Inc.
• RECRUITINGPHASE1, PHASE2NCT04104776
  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  Novartis Pharmaceuticals
• ACTIVE NOT RECRUITINGPHASE2NCT03348631
  Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
  National Cancer Institute (NCI)

See all trials for Clear cell adenocarcinoma of the ovary →